Skip to main content
Fig. 6 | BMC Immunology

Fig. 6

From: CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

Fig. 6

CD16 low expression on neutrophils predicted pro-tumor immune status in CRC patients with capecitabine therapy. Peripheral venous blood from CRC patients received single-agent oral capecitabine adjuvant therapy was collected 6–9 months after the therapy and analyzed for different immune cell subsets by flow cytometry. CD16 MFI of peripheral blood neutrophils was calculated by flow cytometry analysis, and the correlations between CD16 MFI of neutrophils and frequencies of CD8+ T cells (a), CD4+ T cells (b), monocytes (c), NK cells (d), cDCs (e) and pDCs (f) among total peripheral blood leukocytes were analyzed by Pearson’s correlation test

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us